Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02332239 · ClinicalTrials.gov registry record · NA

Text-Message-Based Depression Prevention for High-Risk Youth in the ED

A NA study of Depressive Disorder and Violence, sponsored by Rhode Island Hospital.

Completed
Registry status
NA
Development phase
116
Enrollment target
1
Study location

NCT02332239 is a NA study of Depressive Disorder and Violence that has completed, run by Rhode Island Hospital. The registered enrollment target is 116 participants, below the 329-participant average among 47 other Depressive Disorder trials with a reported enrollment target (65% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02332239, a NA study of Depressive Disorder and Violence, has completed, sponsored by Rhode Island Hospital.

COMPLETED
Registry status
NA
Development phase
116 participants
Enrollment target
1
Study location

Study Summary

The purpose of this randomized controlled study is to evaluate acceptability and feasibility, and to gather preliminary data about efficacy, of "iDOVE," a brief emergency department introductory session + longitudinal automated text-message depression prevention program for high-risk teens.

Interventions

  • BEHAVIORAL iDOVE Intervention (ED+text)
  • BEHAVIORAL Control (EUC)

Study Locations (1)

Rhode Island

  • Rhode Island Hospital Emergency Department - Providence

Trial Details

FieldValue
Enrollment Target 116 participants
Start Date 2015-02
Est. Completion 2017-05
Phase NA

Sponsor

Rhode Island Hospital

130 total trials

What the Registry Record Tells You About NCT02332239

The ClinicalTrials.gov registry entry for NCT02332239 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 116 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 329-participant average among 47 other Depressive Disorder trials with a reported enrollment target (65% lower). The listed sponsor is Rhode Island Hospital, which has 130 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Depressive Disorder appearing as the primary indexed condition, and to 2 interventions - of which iDOVE Intervention (ED+text) is the first listed.

NCT02332239 reports 1 study location spanning 1 distinct geographic area - top geographies include Rhode Island.

Frequently Asked Questions

What is clinical trial NCT02332239 about?

NCT02332239 is a clinical study titled "Text-Message-Based Depression Prevention for High-Risk Youth in the ED". The purpose of this randomized controlled study is to evaluate acceptability and feasibility, and to gather preliminary data about efficacy, of "iDOVE," a brief emergency department introductory session + longitudinal automated text-message depression prevention program for high-risk teens.

What is the current status of trial NCT02332239?

This trial is currently completed. It is a NA study. The enrollment target is 116 participants. The study started on 2015-02. Estimated completion is 2017-05.

What conditions does trial NCT02332239 study?

This clinical trial studies the following conditions: Depressive Disorder, Violence.

What interventions are being tested in trial NCT02332239?

The interventions under investigation include: iDOVE Intervention (ED+text) (BEHAVIORAL), Control (EUC) (BEHAVIORAL).

Who is sponsoring clinical trial NCT02332239?

This trial is sponsored by Rhode Island Hospital, which has 130 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02332239 being conducted?

This trial has 1 study location across Rhode Island. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Depressive Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.